Fixed-dose combination therapy (polypill) for the prevention of cardiovascular disease.
Huffman, Mark D;
de Cates, Angharad N;
Ebrahim, Shah;
(2014)
Fixed-dose combination therapy (polypill) for the prevention of cardiovascular disease.
JAMA, 312 (19).
pp. 2030-2031.
ISSN 0098-7484
DOI: https://doi.org/10.1001/jama.2014.13616
Permanent Identifier
Use this Digital Object Identifier when citing or linking to this resource.
CLINICAL QUESTION: Is fixed-dose combination therapy (polypill) that combines antiplatelet, blood pressure-lowering, and cholesterol-lowering medications into a single pill associated with improved cardiovascular disease (CVD) risk factors or reduced all-cause mortality or fatal and nonfatal CVD events? Is the polypill associated with an increase in adverse events? BOTTOM LINE: Polypills are associated with greater reductions in systolic blood pressure and total cholesterol compared with usual care, placebo, or active comparators, but also with a 19% higher risk of any adverse event. Due to limited power from available evidence, the association of polypills with all-cause mortality or fatal and nonfatal CVD events is uncertain.